Mary Beth Skylis - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Mary Beth Skylis's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Mary Beth Skylis
Verified
Columnist, Parkinson's News Today
Beats
LGBTQ, Mental Health, Lifestyle, Lifestyle, Sex Work
Anything in the red tops.
Content
By Margarida Maia Verified, Michela Luciano, Mary Beth Skylis, Andrea Lobo| Parkinson's News Today Verified Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes of drugs.
By Mary Beth Skylis| Travel + Leisure Verified Title:WriterEducation:Aquinas CollegeLocation:Lakewood, COExpertise:Outdoor Adventure,Backpacking,Climbing Mary Beth is a Colorado-based freelance writer with a background in adventure travel. She first started publishing her work in 2015 after hiking the 2,200-mile Appalachian Trail. Since her debut hike, she's also tackled the Colorado Trail, trekked through the Himalayas, navigated the jungles of South America, and the slot canyons of western USA.
By Margarida Maia Verified, Michela Luciano, Mary Beth Skylis, Andrea Lobo| Parkinson's News Today Verified Tavapadon, an orally available small molecule being developed for Parkinson’s disease, was generally safe and eased motor symptoms within one month of being administered at either a fixed or flexible dose to adults with early-stage disease. It also reduced the risk of common side effects typically associated with similar classes of drugs.
Company Info
Parkinson's News Today